pharmaphorum

AUGUST 7, 2020

Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. Roche, AstraZeneca, Novo Nordisk, and Sanofi all shot up the rankings in the first edition of the report since the start of the coronavirus crisis, but the big loser was Gilead Sciences, falling 71 places to 74 in the list.

Nursing Homes 104

Nursing Homes Vaccines Immunity Immunization 104

Pharmaceutical Technology

JULY 7, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).

40

40

Pharmaceutical Technology

JULY 7, 2023

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus Infections and Coronavirus Disease 2019 (COVID-19) is under clinical development by Blue Sky Immunotherapies and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN).

40

40

pharmaphorum

AUGUST 18, 2020

million euro project funded by European Union cash and European pharma companies is a work stream that aims to find drugs that work against coronavirus strains that may emerge in the future. The trick is to look for proteins that are used across all coronavirus types and tend not to vary much from one virus species to another.

119

119

pharmaphorum

FEBRUARY 18, 2021

GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and other respiratory viruses. The first is an expansion of their current functional genomics collaboration to develop potential pan-coronavirus therapeutics to now include other respiratory virus targets.

110

110

pharmaphorum

AUGUST 14, 2020

Catch up on the latest coronavirus vaccine and digital tech news in our roundup of this week’s biggest stories. Russia has become the first country in the world to approve a coronavirus vaccine , amid scepticism from international experts who have been unable to review or verify clinical data from the jab called ‘Sputnik V’.

Vaccines 98

Vaccines Hospitals 98

pharmaphorum

OCTOBER 20, 2020

The UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will be deliberately infected in a controlled environment with coronavirus to test whether a vaccine is effective. hVIVO will also be expanding its clinical operations in London to conduct the trial.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

AUGUST 16, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.

Vaccines 103

Vaccines Immunity Immunization 103

pharmaphorum

DECEMBER 7, 2020

China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion. Sinovac has a coronavirus vaccine in late-stage development, which is undergoing large-scale trials in Brazil, Pakistan, Indonesia and Chile. A further 1.8

Vaccines 57

Vaccines Immunity Immunization 57

pharmaphorum

APRIL 8, 2020

This pharmaphorum webinar will take place on 8th April and comes as the COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus vaccine. Thrown into even sharper relief than usual are the needs faced by all vaccine trials to balance study speed, data accuracy and patient experience.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MARCH 9, 2021

The company claims the app can serve as a diagnostics tool to help users identify underlying illnesses and even help curb the spread of coronavirus. The app was also 100% effective in correctly diagnosing COVID-19 in people with no symptoms but who had tested positive for the virus, although it had a high false positive rate among this group.

125

125

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. The vaccine is top of the list of 35 potential coronavirus vaccines in clinical development, according to a list maintained by the World Health Organization.

Vaccines 102

Vaccines Immunity Immunization 102

pharmaphorum

JANUARY 20, 2021

UK biotech ConserV Bioscience has joined with California’s Lawrence Livermore National Laboratory to develop broad-spectrum coronavirus vaccines as concerns mount over potentially more infectious strains emerging in the UK, South Africa and Brazil. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MAY 14, 2021

Concerns are emerging in the UK about the spread of the coronavirus variant that has caused a surge in cases in India, prompting warnings that lockdown easing plans may need a rethink. ” Latest figures show total coronavirus infections holding steady at around 2,600 new cases a day, with 11 deaths recorded yesterday across the UK.

Vaccines 98

Vaccines Hospitals 98

European Pharmaceutical Review

AUGUST 17, 2023

The National Institutes of Health (NIH) has chosen contract development, and manufacturing organisation (CDMO) Exothera SA to develop the manufacturing process for its intranasal vaccine against SARS-CoV-2 coronavirus to treat COVID-19. MHRA authorises new COVID-19 vaccine What will the intranasal vaccine manufacturing project involve?

Vaccines 91

Vaccines Immunity Immunization 91

Pharmaceutical Technology

JUNE 24, 2022

Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant.

Vaccines 105

Vaccines 105

pharmaphorum

NOVEMBER 11, 2020

The preliminary assessment is based on 20 coronavirus cases split between the vaccinated and placebo arms of the study at 21 days, according to a press statement issued this morning by the Gamaleya Institute which developed the shot and the Russian Direct Investment Fund (RDIF). The country has had more than 1.8 Requests for more than 1.2

Vaccines 113

Vaccines 113

pharmaphorum

OCTOBER 27, 2020

Russia’s sovereign wealth fund has filed applications with the World Health Organization (WHO) that if approved could see the Sputnik V coronavirus vaccine backed for use in many countries around the world. The vaccine is based on two adenovirus vectors (Ad5 and Ad26) fused with the spike protein from the SARS-CoV-2 coronavirus.

Vaccines 101

Vaccines 101

pharmaphorum

OCTOBER 6, 2020

The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race with a rival from AstraZeneca and Oxford University. According to latest figures from the World Health Organization, there are 42 potential COVID-19 vaccines in clinical development.

Vaccines 57

Vaccines Immunity Immunization 57

pharmaphorum

MAY 27, 2020

Insights on the impact of COVID-19 for pharma and biotech companies and considerations for a post-coronavirus new normal in life sciences and healthcare. It will also discuss the UK response to the emergency, clinical trials and how digital health has met the COVID-19 challenge for healthcare professionals, patients and industry.

40

40

Pharmaceutical Technology

AUGUST 1, 2022

Furthermore, the parties will collaborate on the joint development of systems that accelerate the latest designs into clinical usage. The human health product candidates of GreenLight are currently in the pre-clinical stage.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

SEPTEMBER 17, 2020

An interim analysis of the BLAZE-1 clinical trial showed a reduced rate of hospitalisation in patients treated with Lilly’s LY-CoV555, an antibody that neutralises the SARS-CoV-2 coronavirus, in a phase 2 trial. The rate of resistance variants was numerically higher in treated patients (8%) versus placebo (6%).

Hospitals 128

Hospitals Vaccines 128

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. Those deals cover 200 million doses of J&J’s Ad26.COV2.S

Vaccines 109

Vaccines Immunity Immunization 109

pharmaphorum

FEBRUARY 1, 2022

However, one benefit is that it accelerated innovations underway to solve long-standing clinical process issues. The pandemic turbo-charged trial decentralisation,” says Caroline Redeker, senior vice president, corporate development at Advanced Clinical. “We

52

52

FADIC

AUGUST 11, 2023

Check Now about Coronavirus Resource Information Center. Check Now the FADIC Book store and Buy books in different specialities. Simple random sampling: Definition, examples, and how to do it The post Antibiotic Interactions: Combinations to Avoid for Safe Medication appeared first on FADIC.

98

98

pharmaphorum

SEPTEMBER 17, 2020

Side-effects that caused AstraZeneca to pause its coronavirus vaccine trial are unlikely to be caused by the shot according to documents posted online and cited in other press reports – but the FDA is yet to give the go ahead for US testing to restart. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Vaccines 104

Vaccines Documentation Immunity Immunization 104

pharmaphorum

JUNE 23, 2022

The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers “compounds and pharmaceutically acceptable salts which inhibit coronavirus replication activity, and methods of treating a coronavirus infection” and was awarded earlier this month.

Compounding 52

Compounding Documentation 52

pharmaphorum

FEBRUARY 18, 2021

The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study. The body’s immune response to the coronavirus is not limited to antibodies with CD8+ T-cells also playing roll combating infections.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

DECEMBER 7, 2020

Tuesday has been dubbed “V-day” in the UK, when the first doses of Pfizer/BioNTech’s coronavirus vaccine will be distributed to the public outside of a clinical trial. However the waiting list for the vaccine fridges is expected to grow as more and more companies authorise various coronavirus vaccines.

Vaccines 98

Vaccines 98

pharmaphorum

APRIL 27, 2021

Following the success of the coronavirus vaccine developed with AstraZeneca, Oxford University’s Jenner Institute has unveiled trial results showing its experimental malaria shot could be around 77% effective. The post Oxford’s malaria shot set for phase 3 test after ‘unprecedented’ 77% efficacy appeared first on.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

OCTOBER 16, 2020

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. Russia is the world’s fourth-most affected country by the coronavirus pandemic with a total of 1.37 Chinese inactivated vaccine safe.

Vaccines 98

Vaccines 98

pharmaphorum

SEPTEMBER 15, 2020

It started phase 3 testing in May to treat the so-called ‘cytokine storm’ that leaves some people with coronavirus infections fighting for their lives with acute respiratory distress syndrome (ARDS), and Humanigen is hopeful for data that could support an emergency okay.

Mayo Clinic 97

Mayo Clinic Immunity Immunization Hospitals 97

pharmaphorum

NOVEMBER 24, 2020

The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. The next analysis for Sputnik V will be made when there are 78 confirmed coronavirus cases. So far it has accepted orders for 1.2

Vaccines 109

Vaccines Immunity Immunization 109

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preclinical and clinical studies have made it possible to provisionally approve the vaccine under the current Russian coronavirus regulations.

Immunity 106

Immunity Immunization Vaccines Hospitals 106

pharmaphorum

MARCH 5, 2021

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response to some long-standing issues with the clinical trials process. .

Pharmaceutical Companies 57

Pharmaceutical Companies Pharmaceutical Companies 57

Pharmaceutical Technology

AUGUST 15, 2022

The updated, Omicron-containing bivalent vaccine that acts on two coronavirus variants is indicated as a booster dose for active immunisation for the prevention of Covid-19 in people of this age group. The latest MHRA decision is based on findings from the Phase II/III clinical trial, where the mRNA-1273.214 vaccine met all primary endpoints.

Vaccines 85

Vaccines Immunity Immunization 85

pharmaphorum

MARCH 19, 2021

Since the third quarter of last year DeepVerge’s scientists have been working to transform an AI-based water contamination detection system into a unit that tests for the presence of the coronavirus. A large clinical trial is ongoing in Dubai.

Documentation 145

Documentation Vaccines 145